Skip to main content

Ileocystoplasty

Ileocystoplasty is the most commonly performed type of augmentation cystoplasty, using a detubularized segment of ileum anastomosed to the native bladder to increase bladder capacity and improve compliance.[1][2] It remains the gold standard for surgical bladder augmentation when conservative therapies have failed.[1]

Indications​

Ileocystoplasty is indicated for patients with a poorly compliant or overactive bladder refractory to conservative management (anticholinergics, β3-agonists, intradetrusor botulinum toxin).[1] Common underlying conditions:

  • Neurogenic bladder (myelodysplasia / spina bifida, spinal cord injury, tethered cord, sacral agenesis)
  • Bladder exstrophy / cloacal exstrophy
  • Posterior urethral valves
  • Idiopathic detrusor overactivity[1][2][3]

The primary goals are upper-tract protection, continence, and quality of life.

Contraindications​

Relative and absolute contraindications:[4]

  • Significant renal insufficiency — increases the consequences of metabolic acidosis. The cited historical review does not establish a universal contemporary creatinine-clearance exclusion threshold; assess renal reserve, baseline acidosis, and alternatives individually.
  • Inability or unwillingness to perform clean intermittent catheterization (CIC) when CIC is anticipated postoperatively.
  • Active inflammatory bowel disease, prior pelvic radiation precluding healthy bowel use.
  • Patient/caregiver unable to commit to lifelong follow-up.

Surgical Technique​

The standard open technique:[1][5][6]

  1. Bowel-segment selection: ~15–40 cm of ileum, selected to preserve as much terminal ileum and the ileocecal valve as feasible. A fixed distance does not guarantee preserved vitamin B₁₂ or bile-salt absorption; record the actual segment and length used.
  2. Bowel continuity restoration: Side-to-side ileoileal anastomosis (stapled or hand-sewn).
  3. Detubularization: The isolated ileal segment is opened along its antimesenteric border — disrupts coordinated peristaltic contractions, converting the segment into a low-pressure reservoir.[6]
  4. Reconfiguration: The opened segment is folded into a U- or S-shaped patch to maximize volume and minimize pressure.
  5. Cystotomy: Native bladder is bivalved (sagittal cystotomy).
  6. Anastomosis: Reconfigured ileal patch is sutured to the opened bladder in a watertight fashion.

Clam ileocystoplasty: Bowel patch construction and bladder augmentation

Ileum is opened along the antimesenteric border, reconfigured into a patch, and joined to the opened native bladder. This is the reservoir principle, not a complete operation. Mesenteric blood supply, bowel continuity, drainage and lifelong follow-up are not drawn. (Original WARWIKI schematic; see the figure source record and review limits.)

Concomitant procedures​

Frequently performed at the time of ileocystoplasty:[1][7]

  • Catheterizable channel (Mitrofanoff appendicovesicostomy or Monti channel) for patients who cannot catheterize per urethra.
  • Ureteral reimplantation for selected anatomic indications; high-pressure reflux can improve with augmentation alone, so reimplantation is not automatic.
  • Bladder-neck procedures for incontinence (sling, bladder-neck closure).

Minimally invasive approaches​

Laparoscopic and robot-assisted ileocystoplasty are technically feasible. The cited small series do not establish shorter stay or less pain than open surgery, and procedural complexity remains substantial.[3][5][8][9]

Outcomes​

  • Bladder capacity: increased from mean 111 → 788 mL at 12 months in a 23-patient laparoscopic series; this is not a target capacity for every patient.[8]
  • Maximum detrusor pressure: significant decrease (e.g., 92 → 15 cm H₂O).[8]
  • Continence: older mixed-segment cohorts reported 82–95%, often after additional outlet procedures; these are not isolated ileocystoplasty cure rates.[6][7]
  • Upper-tract protection: renal function was maintained or improved in 91% of a historical 129-patient cohort comprising several intestinal augmentations and replacements, rather than ileocystoplasty alone.[6][10]
  • Patient satisfaction: in a long-term SCI cohort (mean 14.7 yr), 13/14 respondents would recommend the procedure.[11]

In a retrospective 84-patient mixed-segment study, postoperative pathologic contractions occurred in 26% of 31 ileal, 43% of 35 colonic, and 50% of 18 gastric reconstructions. This favors ileum within that series but does not establish universal superiority or absence of contractions.[12]

Complications​

Significant long-term morbidity requiring lifelong surveillance.[1][13][14]

  • Urinary tract stones — most common late complication, 18–36%. Risk factors: continent catheterizable stomas, bladder exstrophy, mucus production, urinary stasis. ~50% recur after stone removal.[7][10][14]
  • Urinary tract infections — distinguish asymptomatic bacteriuria from symptomatic infection. Balanca reported at least one febrile UTI in 55.8% of 77 SCI patients over median 13 years, not recurrent UTI in every affected patient. Taghavi reported symptomatic UTI in 36/71 (51%) children with mixed augmentation types over median 4.5 years.[15][16]
  • Bladder perforation — Szymanski estimated 10-year risk of 9.6% with detubularized reconfigured ileocystoplasty versus 23.7% without it in a spina bifida cohort. These are observational time-to-event estimates, not universal rates. Overdistension and unreliable emptying are important preventable risks, but perforation may have other causes.[8][14]
  • Hyperchloremic metabolic acidosis — most common metabolic abnormality, from chloride and ammonium reabsorption by ileal mucosa. Severity depends on segment length, contact time with urine (regular CIC matters), and baseline renal function. Treat documented acidosis with an individualized alkali regimen; potassium-containing therapy requires particular caution with renal impairment or hyperkalemia.[13][17][18]
  • Vitamin B₁₂ deficiency — monitor according to ileal use and nutritional risk. The cited 32% supplementation figure comes from 94 Mainz ileocecal-pouch diversion patients, including low-normal levels; it is not an ileocystoplasty deficiency rate.[17]
  • Bowel dysfunction — diarrhea or altered bowel habits from loss of the ileocecal valve or shortened bowel; small-bowel obstruction in ~4.5%.[7][14]
  • Reoperation — Szymanski estimated a 43.9% 10-year risk in a mixed-era spina bifida augmentation cohort. A separate 114-adult continent cutaneous ileocecocystoplasty cohort had 42.1% additional surgery over median 40 months and 20.2% channel revision; do not apply its channel outcomes to isolated ileocystoplasty.[14][19]

Malignancy Risk​

Malignancy after intestinal augmentation is uncommon but important. A systematic review across augmentation types reported probabilities of 0–5.5% and mean latency 19 years; this is not an ileocystoplasty-specific pooled risk.[20][21]

  • Adenocarcinoma (often signet-ring features) is the most common histologic type, ~52% of post-augmentation malignancies.[20][22]
  • Tumors predominantly arise at the entero-vesical anastomotic site.[20]
  • Frequently diagnosed at advanced stage with poor prognosis (1-year survival ~56% in one series).[23]
  • Whether augmentation itself is an independent risk factor (vs the underlying congenital bladder abnormality) remains debated — one matched cohort study found no significant difference in cancer incidence between augmented patients and controls (4.6% vs 2.6%, p=0.54).[24]
  • Molecular profiling shows these tumors resemble gastrointestinal adenocarcinomas, with frequent TP53, KRAS, and MYC alterations and potentially targetable mutations in the majority.[25]

Older observational publications recommended scheduled endoscopy after five years, but this is not the current AUA/SUFU approach to stable asymptomatic NLUTD.[26] Investigate gross hematuria, recurrent unexplained symptomatic UTI, or suprapubic pain promptly with cystoscopy and an appropriate additional workup, regardless of time since surgery. Routine screening benefit remains uncertain, including after gastric augmentation.[2][27]

Long-Term Follow-Up​

The AUA/SUFU NLUTD guideline recommends annual lifelong surveillance:[27]

  • Focused history, physical exam, and symptom assessment.
  • Basic metabolic panel to monitor for acidosis and electrolyte disturbances.
  • Urinary tract imaging (renal ultrasound for hydronephrosis and stones).

Additional considerations: periodic vitamin B₁₂ levels, bone density assessment in at-risk patients, cystoscopy as clinically indicated.[17][18]

Alternatives​

Other bowel segments (sigmoid, stomach) can be used for augmentation, each with distinct complication profiles. Tissue-engineering approaches using biodegradable scaffolds seeded with urothelial and smooth muscle cells remain promising but experimental.[1]

References​

1. Cheng PJ, Myers JB. "Augmentation Cystoplasty in the Patient With Neurogenic Bladder." World Journal of Urology. 2020;38(12):3035-3046. doi:10.1007/s00345-019-02919-z

2. Biers SM, Venn SN, Greenwell TJ. "The Past, Present and Future of Augmentation Cystoplasty." BJU International. 2012;109(9):1280-93. doi:10.1111/j.1464-410X.2011.10650.x

3. Barashi NS, Rodriguez MV, Packiam VT, Gundeti MS. "Bladder Reconstruction With Bowel: Robot-Assisted Laparoscopic Ileocystoplasty With Mitrofanoff Appendicovesicostomy in Pediatric Patients." Journal of Endourology. 2018;32(S1):S119-S126. doi:10.1089/end.2017.0720

4. Smith RB, van Cangh P, Skinner DG, Kaufman JJ, Goodwin WE. "Augmentation Enterocystoplasty: A Critical Review." The Journal of Urology. 1977;118(1 Pt 1):35-9. doi:10.1016/s0022-5347(17)57878-7

5. Elliott SP, Meng MV, Anwar HP, Stoller ML. "Complete Laparoscopic Ileal Cystoplasty." Urology. 2002;59(6):939-43. doi:10.1016/s0090-4295(02)01605-9

6. Mitchell ME, Piser JA. "Intestinocystoplasty and Total Bladder Replacement in Children and Young Adults: Followup in 129 Cases." The Journal of Urology. 1987;138(3):579-84. doi:10.1016/s0022-5347(17)43264-2

7. Shekarriz B, Upadhyay J, Demirbilek S, Barthold JS, González R. "Surgical Complications of Bladder Augmentation: Comparison Between Various Enterocystoplasties in 133 Patients." Urology. 2000;55(1):123-8. doi:10.1016/s0090-4295(99)00443-4

8. el-Feel A, Abdel-Hakim MA, Abouel-Fettouh H, Abdel-Hakim AM. "Laparoscopic Augmentation Ileocystoplasty: Results and Outcome." European Urology. 2009;55(3):721-7. doi:10.1016/j.eururo.2008.03.102

9. Lorenzo AJ, Cerveira J, Farhat WA. "Pediatric Laparoscopic Ileal Cystoplasty: Complete Intracorporeal Surgical Technique." Urology. 2007;69(5):977-81. doi:10.1016/j.urology.2007.02.029

10. Chang JW, Kuo FC, Lin TC, et al. "Long-Term Complications and Outcomes of Augmentation Cystoplasty in Children With Neurogenic Bladder." Scientific Reports. 2024;14(1):4214. doi:10.1038/s41598-024-54431-z

11. Gurung PM, Attar KH, Abdul-Rahman A, et al. "Long-Term Outcomes of Augmentation Ileocystoplasty in Patients With Spinal Cord Injury: A Minimum of 10 Years of Follow-Up." BJU International. 2012;109(8):1236-42. doi:10.1111/j.1464-410X.2011.10509.x

12. Juhász ZS, Kispál Z, Kardos D, Vajda P. "Long-Term Urodynamic Findings Following Colo-, Gastro- And Ileocystoplasty." Pediatric Surgery International. 2024;40(1):131. doi:10.1007/s00383-024-05714-z

13. Gilbert SM, Hensle TW. "Metabolic Consequences and Long-Term Complications of Enterocystoplasty in Children: A Review." The Journal of Urology. 2005;173(4):1080-6. doi:10.1097/01.ju.0000155248.57049.4e

14. Szymanski KM, Misseri R, Whittam B, et al. "Additional Surgeries After Bladder Augmentation in Patients With Spina Bifida in the 21st Century." The Journal of Urology. 2020;203(6):1207-1213. doi:10.1097/JU.0000000000000751

15. Balanca A, Even A, Malot C, et al. "Long-Term Clinical and Urodynamic Effectiveness of Augmentation Ileocystoplasty With Supra-Trigonal Cystectomy in Individuals With Spinal Cord Injury." World Journal of Urology. 2022;40(8):2121-2127. doi:10.1007/s00345-022-04028-w

16. Taghavi K, O'Hagan LA, Bortagaray J, et al. "Complication Profile of Augmentation Cystoplasty in Contemporary Paediatric Urology: A 20-Year Review." ANZ Journal of Surgery. 2021;91(5):1005-1010. doi:10.1111/ans.16736

17. Pfitzenmaier J, Lotz J, Faldum A, et al. "Metabolic Evaluation of 94 Patients 5 to 16 Years After Ileocecal Pouch (Mainz Pouch 1) Continent Urinary Diversion." The Journal of Urology. 2003;170(5):1884-7. doi:10.1097/01.ju.0000091900.57347.ee

18. Cruz DN, Huot SJ. "Metabolic Complications of Urinary Diversions: An Overview." The American Journal of Medicine. 1997;102(5):477-84. doi:10.1016/S0002-9343(97)00020-X

19. Cheng PJ, Keihani S, Roth JD, et al. "Contemporary Multicenter Outcomes of Continent Cutaneous Ileocecocystoplasty in the Adult Population Over a 10-Year Period: A Neurogenic Bladder Research Group Study." Neurourology and Urodynamics. 2020;39(6):1771-1780. doi:10.1002/nau.24420

20. Biardeau X, Chartier-Kastler E, Rouprêt M, Phé V. "Risk of Malignancy After Augmentation Cystoplasty: A Systematic Review." Neurourology and Urodynamics. 2016;35(6):675-82. doi:10.1002/nau.22775

21. Ali-El-Dein B, El-Tabey N, Abdel-Latif M, Abdel-Rahim M, El-Bahnasawy MS. "Late Uro-Ileal Cancer After Incorporation of Ileum Into the Urinary Tract." The Journal of Urology. 2002;167(1):84-8.

22. Anderson JA, Matoso A, Murati Amador BI, et al. "Invasive Poorly Differentiated Adenocarcinoma of the Bladder Following Augmentation Cystoplasty: A Multi-Institutional Clinicopathological Study." Pathology. 2021;53(2):214-219. doi:10.1016/j.pathol.2020.07.005

23. Garnier S, Vendrell J, Boillot B, et al. "Malignancy After Augmentation Enterocystoplasty: A Nationwide Study of Natural History, Prognosis and Oncogene Panel Analysis." The Journal of Urology. 2020;204(1):136-143. doi:10.1097/JU.0000000000000752

24. Higuchi TT, Granberg CF, Fox JA, Husmann DA. "Augmentation Cystoplasty and Risk of Neoplasia: Fact, Fiction and Controversy." The Journal of Urology. 2010;184(6):2492-6. doi:10.1016/j.juro.2010.08.038

25. Stohr BA, Chan E, Anderson JA, et al. "Molecular Characterization of Adenocarcinomas Arising in the Urinary Bladder Following Augmentation Cystoplasty: A Multi-Institutional Study." Human Pathology. 2022;129:98-102. doi:10.1016/j.humpath.2022.09.003

26. Kälble T, Hofmann I, Riedmiller H, Vergho D. "Tumor Growth in Urinary Diversion: A Multicenter Analysis." European Urology. 2011;60(5):1081-6. doi:10.1016/j.eururo.2011.07.006

27. Ginsberg DA, Boone TB, Cameron AP, et al. "The AUA/SUFU Guideline on Adult Neurogenic Lower Urinary Tract Dysfunction: Treatment and Follow-Up." The Journal of Urology. 2021;206(5):1106-1113. doi:10.1097/JU.0000000000002239